Drugs / BI 754132
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04002310 | Jul 2019 → Aug 2022 | age-related macular degeneration | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 754132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04002310 ↗ |
| Route | Intravitreal | “administered intravitreally” NCT04002310 ↗ |